3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Motor Activity
1
Lymphoma
1
Leukemia
1
Interventions
Cyclophosphamide
172
Rituximab
157
Specimen Handling
116
Biopsy
93
Magnetic Resonance Spectroscopy
90
Vincristine
89
Doxorubicin
83
Prednisone
81
fludarabine
70
venetoclax
67
obinutuzumab
62
ibrutinib
55
Lenalidomide
55
Dexamethasone
55
Cytarabine
49
Methotrexate
46
acalabrutinib
43
Etoposide
41
blinatumomab
40
CT-P10
39
Bendamustine Hydrochloride
37
fludarabine phosphate
33
Gemcitabine
33
prednylidene
32
Calcium Dobesilate
32
deltacortene
31
zanubrutinib
30
pembrolizumab
29
glofitamab
28
Nivolumab
28
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Nadolol
×
Lymphoid
×
90 days
×
Clear all
NCT06643221
2026-06-05
Allo-X
University of Arizona
Phase EARLY_PHASE1
Recruiting
200 enrolled